Company news

Clene Inc. news in 2024

Clene Inc.'s news releases, calls and decks from 2024, newest first.

View company

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

December 18, 2024

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

December 9, 2024

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

November 12, 2024

Clene to Present at Upcoming October Conferences

October 8, 2024

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

September 30, 2024

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

September 29, 2024

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

September 15, 2024

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

August 6, 2024

Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

August 5, 2024

Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

August 4, 2024

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

July 10, 2024

Clene Announces 1-for-20 Reverse Stock Split

July 8, 2024

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

June 23, 2024

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

June 20, 2024

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

June 17, 2024

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 27, 2024

Clene to Present at Upcoming May Conferences

May 13, 2024

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

May 7, 2024

Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

April 15, 2024

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

March 14, 2024

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

March 12, 2024

Clene to Present at the 36th Annual ROTH Conference

March 6, 2024

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

February 28, 2024

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

February 21, 2024

Clene Inc. announces positive results from CNM-Au8 results from MS trial

February 4, 2024

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension

January 7, 2024

Decks in 2024